Barclays Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective increased by analysts at Barclays from $145.00 to $160.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Barclays‘s price target indicates a potential downside of 6.04% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC set a $175.00 price target on Gilead Sciences in a report on Friday, October 30th. Bank of America lifted their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research note on Tuesday, October 20th. Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Finally, Argus set a $190.00 price target on shares of Gilead Sciences in a report on Thursday. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $171.63.

View Our Latest Research Report on GILD

Gilead Sciences Trading Up 1.3%

Shares of NASDAQ:GILD traded up $2.21 during midday trading on Monday, reaching $170.28. The company’s stock had a trading volume of 627,308 shares, compared to its average volume of 6,771,567. The firm has a market capitalization of $211.21 billion, a price-to-earnings ratio of -53.95 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The firm has a 50 day moving average price of $155.10 and a two-hundred day moving average price of $141.80. Gilead Sciences has a fifty-two week low of $116.88 and a fifty-two week high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.47 EPS. As a group, analysts forecast that Gilead Sciences will post -0.97 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares in the company, valued at $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 102,619 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total transaction of $17,974,744.04. Following the sale, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at approximately $96,632,794.28. The trade was a 15.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 211,709 shares of company stock worth $35,234,427 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of Nova Scotia bought a new position in shares of Gilead Sciences during the second quarter valued at $100,056,000. OMERS ADMINISTRATION Corp bought a new stake in Gilead Sciences in the 2nd quarter worth about $55,754,000. Groupe la Francaise increased its holdings in Gilead Sciences by 30.9% in the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after buying an additional 11,712 shares in the last quarter. Baird Financial Group Inc. increased its holdings in Gilead Sciences by 3.6% in the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after buying an additional 10,206 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Gilead Sciences in the 2nd quarter worth about $6,251,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

More Gilead Sciences News

Investors following GILD have been watching these news items:

  • Positive Sentiment: Gilead’s earnings call was characterized as signaling broad growth momentum, offering a positive business outlook, though the provided article details do not specify which products or results drove that assessment. Gilead Sciences Earnings Call Signals Broad Growth Momentum
  • Neutral Sentiment: Gilead appeared in an article about dividend stocks for retirees, but the item supplied no Gilead-specific change to its dividend or outlook. A separate article noted the stock’s strong relative performance over the past year, while discussing weaker longer-term returns. Dividend Stocks for Retirees Gilead’s Relative Performance
  • Negative Sentiment: Zacks Research’s latest headline points to lower earnings expectations. Its detailed estimate changes were mixed, but included cuts to FY2026 EPS (to -$0.86 from -$0.65) and Q4 2026 EPS (to $1.31 from $2.14); it maintained a Hold rating. These downward revisions may weigh on sentiment. Zacks Forecasts Lower Earnings Zacks Estimate Revisions

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Recommended Stories

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.